Prognostic factors of persistently detectable PSA after radical prostatectomy

International Journal of Urology

Volumn 16, Issue 1, 2009, Pages 82-86

  Naselli, Angelo ^a,b   Introini, Carlo ^a   Andreatta, Rossana ^a   Spina, Bruno ^a   Truini, Mauro ^a   Puppo, Paolo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE   (Italy)

Author keywords

Local neoplasm recurrence; Prostate; Prostate specific antigen; Prostatectomy; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR;

AGED; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 58149199900     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02198.x     Document Type: Article

References (13)

1. Cheng WS, Bergstralh EJ, Frydenberg M, Zincke H. Prostate-specific antigen levels after radical prostatectomy and immediate adjuvant hormonal treatment for stage d1 prostate cancer are predictive of early disease outcome. Eur. Urol. 1994 25 : 189 93.
2. Ravery V. The significance of recurrent PSA after radical prostatectomy: Benign versus malignant sources. Semin. Urol. Oncol. 1999 17 : 127 9.
3. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point?. J. Urol. 2001 165 : 1146 51.
4. Moul JW. Variables in predicting survival based on treating 'PSA-only' relapse. Urol. Oncol. 2003 21 : 292 304.
5. Rogers CG, Khan MA, Craig Miller M, Veltri RW, Partin AW. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. Cancer 2004 101 : 2549 56.
6. Sengupta S, Christensen CM, Zincke H et al. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: Natural history and prognostic significance. J. Urol. 2006 176 : 559 63.
7. Montironi R, van der Kwast T, Boccon-Gibod L, Bono AV, Boccon-Gibod L. Handling and pathology reporting of radical prostatectomy specimens. Eur. Urol. 2003 44 : 626 36.
8. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J. Urol. 2001 165 : 119 25.
9. Swindle P, Eastham JA, Ohori M et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol. 2005 174 : 903 7.
10. Vis AN, Schröder FH, van der Kwast TH. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur. Urol. 2006 50 : 258 65.
11. Simon MA, Kim S, Soloway MS. Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive margins. J. Urol. 2006 175 : 40 4.
12. Salomon L, Anastasiadis AG, Johnson CW et al. Seminal vesicle involvement after radical prostatectomy: Predicting risk factors for progression. Urology 2003 62 : 304 9.
13. Freedland SJ, Aronson W, Presti JC Jr. et al. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database. J. Urol. 2003 169 : 2142 6.